Company: SWKH
Filing Date: 2025-03-20
Form Type: 10-K
Source: 0001628280-25-013989
Chunk: 98

Company: SWK Holdings Corp
Filing Date: 2025-03-20
Form: 10-K
Item: Item 1B
Chunk 98
---
3 (in thousands):December 31,20242023Net (gain) loss on equity securities during the period$(180)$799 Add: Net gain (loss) on warrants exercised or cancelled during the period445 $(799)Add: Net loss recognized on equity securities sold during the period(180)— Unrealized loss on equity securities held at the end of the period$85 $— 

52

Note 7. Assets and Liabilities Held for Sale

With an effective date of January 1, 2024, the Company entered into an Option and Asset Purchase Agreement with a strategic partner on March 14, 2024, which granted the strategic partner an exclusive option to acquire certain of Enteris’ assets related to its business of providing CDMO services to third parties, subject to certain exclusions. The strategic partner must exercise the Option by or before January 1, 2026. As we expect the strategic partner to exercise the Option within the next 12 months from the year ended December 31, 2024, certain assets and liabilities of the Enteris business have been classified as held for sale. The assets and liabilities held for sale represent the major operating assets and liabilities of the Enteris business (i.e. the majority of the Pharmaceutical Development segment) and as such, when the Option is exercised, this segment of the business will no longer exist and only the specialty finance business will remain. The decision to enter into the Option and Asset Purchase Agreement was made to align with the overall strategy to focus on the specialty finance business. The following table summarizes the assets and liabilities held for sale:December 31, 2024Assets:Inventory$354 Property & equipment, net4,635 Intangible assets, net209 Other non-current assets1,200 Total assets held for sale, net$6,398 Liabilities:Accounts payable & accrued liabilities$268 Other non-current liabilities987 Total liabilities held for sale$1,255 During the year ended December 31, 2024, there was not a strategic shift for the Company, and accordingly, the Pharmaceutical Development segment does not meet the criteria to be classified as a discontinued operation. As a result, we will continue to report our operational results for the Pharmaceutical Development segment until the sale. The following table shows the net loss before taxes for Enteris (in thousands):December 31,20242023Net loss before taxes$(3,718)$(9,763)

53

Note